

# **Pathophysiology of heart failure**

Victoria Rotaru

# REGULATION OF CARDIAC PERFORMANCE AND OUTPUT

- Cardiac output (the efficiency of the heart as a pump =  $SV * HR = 3,5-8,0$  l/minute)
- Cardiac reserve
- Preload (ventricular filling)
- After load (resistance to ejection of blood from the heart)
- Cardiac contractility
- Heart rate

# Heart rate

It determines the frequency with which blood is ejected from the heart

# **Stroke volume**

It is a function of preload, afterload,  
and myocardial contractility

# Preload

The volume or loading conditions of the ventricles at the end of diastole; just before the onset of systole;

# After load


Pressure or tension work of the heart; the pressure that the heart must generate to move blood from the filled heart

**Systemic (peripheral vascular resistance)**

**Ventricular wall tension**

# Cardiac contractility

Ability of the heart to change its force of contraction without changing its resting (diastolic length)





# Heart failure


It reflects a fundamental abnormality in effective mechanical performance of the heart, resulting in cardiac output inadequate to meet the body's needs

# Heart failure


May be manifest by :

- a) decrease in cardiac output and/or
- b) damming of blood in the veins  
behind the left or right side of the  
heart


# Systolic Versus Diastolic Dysfunction




# Right versus Left ventricular Dysfunction



### Normal



### Pulmonary edema



**TABLE 28-1****Causes of Heart Failure****Impaired Cardiac Function****Myocardial Disease**

Cardiomyopathies

Myocarditis

Coronary insufficiency

Myocardial infarction

**Valvular Heart Disease**

Stenotic valvular disease

Regurgitant valvular disease

**Congenital Heart Defects****Constrictive Pericarditis****Excess Work Demands****Increased Pressure Work**

Systemic hypertension

Pulmonary hypertension

Coarctation of the aorta

**Increased Volume Work**

Arteriovenous shunt

Excessive administration  
of intravenous fluids**Increased Perfusion Work**

Thyrotoxicosis

Anemia

# PRECIPITATING CAUSES

- **Cardiac factors:**
- *Inflammatory causes* (rheumatic myocarditis, infective endocarditis)
- *Negative inotropic agents* (beta blockers, Ca channels blockers, antiarrhythmics)
- *Myocardial ischemia*
- *Acute mechanic injuries*
- **Extra cardiac factors**
- *Systemic or pulmonary hypertension*
- *Hypervolemia*
- *Hyperkinetic states*

# CAUSES OF HEART FAILURE (UNDERLYING CAUSES)


- **Impaired contraction** ( systolic failure- myocardial infarction, cardiomyopathies, ventricular hypertrophy )
- **Work overload** (**pressure**: systemic hypertension, aortic stenosis, pulmonary hypertension; **volume**: mitral, aortic regurgitation, ventricular septal defect
- **Inadequate heart filling** due to diastolic failure and constrictive pericarditis, cardiac tamponade



# COMPENSATORY MECHANISMS IN HEART FAILURE


- **Immediate (emergent)**
  - **1. Central** (tachycardia, length tension-Frank-Starling mechanism)
  - **2. Peripheral** (redistribution of cardiac output; increased hemoglobin desaturation)
- **Delayed mechanisms**
  - **1. Central** (hypertrophy, cardiac remodeling)
  - **2. Peripheral** (renal retention of fluid)

# Compensatory Mechanisms






# FRANK-STARLING MECHANISM




# **NEURO ENDOCRINE REGULATION OF THE COMPENSATORY MECHANISMS**

- **1. The sympathetic stimulation:**
- **Central effects:** tachycardia , increased contractility, increased diastolic relaxation
- **Peripheral effects:** selective vasoconstriction and flow redistribution; renin release
- **2. The renin-angiotensin-aldosterone system**
- **3. The antidiuretic hormone**
- **4. The prostaglandines**
- **5. The atrial natriuretic peptide**
- **6. Endothelins**
- **7. Inflammatory Mediators (CRP, cytokines )**

# The compensatory mechanisms triggered by a decrease in cardiac output



# The sympathetic stimulation



# NEURO ENDOCRINE REGULATION OF THE COMPENSATORY MECHANISMS

- **Vasoconstrictor:**

1. sympathetic stimulation

2. renin-angiotensin  
aldosterone system

3. ADH

- **Local**

- **Vasodilator**

atrial natriuretic peptide


nitric oxide

prostaglandins

- **Vasodilator**

# Natriuretic Peptides

Cardiac distension  
Sympathetic stimulation  
Angiotensin II  
Endothelin






# Antihypertropic Signaling Pathways

- Have potent natriuretic
- Diuretic
- Vascular smooth muscle effects
- Interact with other neurohumoral mechanisms
- ANP and BNP


## Natriuretic Peptides: Mechanism for Diuresis and Natriuresis

- Inhibition of All-stimulated  $\text{Na}^+$  transport in the proximal tubules
- ↓ vasopressin-stimulated chloride transport in thick ascending limb
- ↓  $\text{NaCl}$  reabsorption in inner medullary collecting duct via cyclic nucleotide-gated cation ( $\text{Na}^+$ ) channel and  $\text{Na}^+, \text{K}^+$  ATPase



-


# Nitric oxide




# Endothelins


Figure 3: Systemic and local effects of Endothelin-1 (ET-1)




## Target Organs of ET-1




# Physiological hypertrophy








# Types of hypertrophy



Fetal genes:	-	+	+	+
Fibrosis:	-	+++	-/+	++
Cellular dysfunction:	-	-/+	-/+	++



# Concentric hypertrophy





# Eccentric hypertrophy





Figure 2 - Chronic phase of left ventricle remodeling.

# Response to pressure and volume overload




# **Cardiac remodeling**

**Clinically manifest as changes in size, shape, and function of the heart after injury or stress stimulation**


# Myocardial Hypertrophy


- **Cellular and molecular remodeling**
- myocyte growth without significant proliferation
- re expression of fetal genes
- alterations in the expression of proteins involved in excitations-contraction coupling
- changes in the energetic and metabolic state of myocyte
- **Changes in the extra cellular matrix (ECM)-** cardiac macrophages, fibroblasts, vascular smooth muscle, endothelial cells)
- hyperplasia
- uncontrolled cardiac fibroblast growth
- increased synthesis of collagen fibers
- Myocardial fibrosis
- ventricular wall stiffness




Process of ventricular remodeling

Figure 4









**Myocardium**

**Vessels**

Noxious stimuli




Increased biomechanical stress to the cardiomyocytes



Increased workload



Adaptive hypertrophic growth



Or undergo apoptosis



Organ enlargement



Cardiac dilation and increased sphericity.



Increased ventricular wall stress



Decreased coronary blood flow



Impaired pump function



Diminished cardiac output



Moreover, interstitial fibrosis is observed, further hindering systolic and diastolic cardiac function




Hypertrophy eventually becomes a maladaptive process



Chronic heart failure and cardiac mortality


# L-type calcium channel




# Molecular Changes Underlying a Transition to Heart Failure

- Intrinsic changes in the cardiomyocyte (reexpression of fetal genes)
- Alterations in the expression of proteins involved in excitation-contraction coupling
- changes in the energetic and metabolic state of the myocyte
- a mismatch between vascular and cardiomyocyte growth
- myocyte death caused by necrosis and apoptosis
- changes in the extra cellular matrix.

# Chromatin Alterations in Cardiac Hypertrophic Signaling



# Impaired Excitation-Contraction Coupling



# Apoptotic changes

Apoptosis is believed to contribute to cardiomyocyte dropout and progressive decline in left ventricular function during chronic heart failure, contributing factors are:

## -Extrinsic Death Receptor Pathway

There is evidence that the Fas/FasL system participates in various types of stress-induced apoptosis in the heart, where cellular stressful stimuli sensitize cardiomyocytes to Fas in vitro. Elevated levels of soluble Fas ligand and Fas mRNA have been found in failing hearts.

## - Intrinsic Mitochondrial Pathway

Release of cytochrome c from the mitochondria and activation of caspase 3 occurs in chronic heart failure patients.

## -Bcl-2 Family

These proteins show either pro-apoptotic (Bcl-2 and Bcl-x<sub>L</sub>) or anti-apoptotic properties (Bax, Bad, Bid, Bnip3), primarily acting through the mitochondrial pathway. Upon hypoxia or mechanical stretch, both kinds of Bcl-2 family proteins were found to be induced during terminal chronic heart failure

# Changes in Heme Oxygenase-1

Heme oxygenase-1 (HO-1, HSP 32) is a member of family of heat shock proteins induced by noxious stimuli.

Heme oxygenase-1 acts as a cell-protective and anti-apoptotically, which means its increased expression indicates increased cell stress.

In chronic heart failure, Heme oxygenase-1 is significantly increased in cardiomyocytes and, to a lesser extent, in arterial smooth muscle cells, endothelial cells and inflammatory cells



# Changes in Metallothionein

Metallothionein is a cell stress protein involved in the inactivation of free reactive oxygen species.

Metallothionein expression is increased in chronic heart.

# Changes in the Cytoskeletal Architecture

## -Tubulin

Tubulin is clearly increased as compared to control tissue from normal human hearts while contractile filaments are reduced.

## -Desmin

There is an increase and disorganization of desmin filaments seen in chronic heart failure, using immunocytochemistry. The irregular distribution of desmin and its mRNA by in situ hybridization in individual myocytes coincided with the occurrence of Z-line streaming and with a lack of contractile filaments.

## -Membrane-associated proteins

These proteins are involved in fixation of sarcomeres to the lateral sarcolemma and stabilization of the T-tubular system.


Vinculin links the cell membrane and actin filaments via talin, paxillin and  $\alpha$ -actinin. Dystrophin is part of a group of proteins (a protein complex) that work together to strengthen muscle fibers and protect them from injury as muscles contract and relax, while Spectrin maintains the plasma membrane integrity and cytoskeletal structure.

In failing human hearts vinculin is increased as are dystrophin, talin, and spectrin.


Data also indicate that some of these changes are found during the compensated stage of heart failure; whereas other changes are found during overt decompensation and are associated with changes in systolic and diastolic function.

The transition from compensated to decompensated heart failure is more than likely related to the overexpression of neurohormones and peptides such as norepinephrine, angiotensin II, and proinflammatory cytokines

A



# HEART FAILURE



Thank You!

